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EDITORIAL
  

The importance of learning outside the
classroom and teaching others
As I sat down to read this year's case report submissions
to our summer supplement I came to the realization that
my decision to not participate in a summer clinical
elective was a mistake. I deprived myself of a valuable
learning experience. My fellow students, who seized
hold of this opportunity, gained precious knowledge that
cannot be learned by sitting in a classroom. Reading
about their experiences made me realize that the famous
physician Sir William Osler was wise when he stated,
"Medicine is learned by the bedside and not in the
classroom. Let not your conceptions of disease come
from words heard in the lecture room or read from the
book. See, and then reason and compare and control.
But see first".
I invite you to read our fellow students¶ case reports and
learn vicariously through their writing as they teach us
the knowledge they gained this summer at the bedside
and not in the classroom. As you read these pages Sarah
O'Connor will teach us an approach to narrow a
differential diagnosis of hypotonia in a pediatric
population. Jeff Landreville will describe the
management of diabetic foot syndrome: a condition we
will all likely encounter during our medical training.
Lilian Wong will teach us why it is important to be an
astute clinician, as she describes the presentation of
Graves¶ disease in an elderly patient. You will also
learn about a rare tumour of the GI tract as Mark Xu
tells the tale of a gastric schwannoma. The importance
of multidisciplinary management is evident as Arielle
Mendel teaches us about the complications of
scleroderma. Lauren Sham reminds us that multiple
sclerosis can also affect children and outlines the
treatment options available to the pediatric population.
Lastly, Abdul Naeem brings to our attention a
complication of topical corticosteroid use that will be
useful knowledge when we prescribe it for our future
patients.

The writing of a case report is a time consuming
process; yet, it is an important method to disseminate
medical knowledge gained through clinical experiences.
Our fellow students are to be commended for
undertaking the challenge and contributing to our
learning beyond the classroom. It is also important that
we recognize the exceptional mentorship role
undertaken by their supervising clinicians. These
clinicians not only undertook the responsibility of
supervising a junior medical student but also provided a
valuable learning experience and the opportunity for
scholarly growth. They are also to be commended for
their efforts. We should all aspire to this standard and
engage in opportunities to teach others during our future
medical careers.
I hope that you enjoy this year's summer supplement and
embrace future opportunities to learn outside the
classroom and teach others.
Melissa J. MacPherson, PhD
Junior Associate Editor
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Grumpy? Recognizing and treating the return
RI*UDYHV¶GLVHDVH
Lilian Lee Yan Wong (Meds 2013)
Faculty Reviewer: Dr. Alice Y.Y. Cheng, MD, FRCPC (Department of Medicine, University of Toronto, Division of
EndRFULQRORJ\DQG0HWDEROLVP&UHGLW9DOOH\+RVSLWDODQG6W0LFKDHO¶V+RVSLWDO)

C ASE
Mrs. RS, a previously healthy 60-year-old lady, was referred to the
Endocrinology clinic by her family physician for assessment of low
TSH and elevated free T4. Over the last 2 months, she had been
experiencing a sensation of neck tightness, mild dysphagia, hoarse
voice, dry nose and some blood in her sputum every week. She also
complained of frequent epistaxis ranging from blood in mucous to
frank red blood from her nose with dizziness. Her appetite was
LQFUHDVHGDQGVKHEHOLHYHGWKDWKHUERG\³GRHVQ¶WDEVRUEDQ\WKLQJ
ZHOO´6KHKDGQRZHLJKWORVV0UV56GRHVQRWKDYHFROGRUKHDW
intolerance. Her other complaints included fatigue, feeling anxious
and irritable, and blurry vision when reading at night-time with the
occasional white flash. Her last optometry visit was 7 years ago.
She admitted to having seasonal allergies that have been improving
over the last 10 years, for which she took over-the-counter allergy
medications in the past. She has also used Nasonex for her nose in
the past, prescribed by her family doctor. Her current medications
include vitamins, Fosamax, calcium, magnesium and glucosamine.
She denied taking any herbal supplements. She has no known drug
allergies.
Her past medical history is significant for thyroid disease 10 years
ago. She was unsure of the type of disease, but recalls taking
medications for 2 years and stopping when her disease subsided. She
also had a history of osteoarthritis (OA) in her hands for 8 years.
Her family history is significant only for OA in her mother. She
denied any family history of thyroid disease. Mrs. RS has also had
no surgeries or hospitalizations.
Her social history revealed that Mrs. RS is originally from the
Philippines, of Chinese decent, and immigrated to Canada 20 years
ago. She lives with her husband, her son, her daughter-in-law and
her 2 grandsons. She works part-time in a coffee shop. She has
never smoked cigarettes or used recreational drugs, and only has one
drink at Christmas.
On examination, Mrs. RS sat comfortably in no apparent distress.
Her weight was 100 lbs with a height of 5 feet 5 inches. Heart rate
was 72 beats/minute and regular with a blood pressure of 110/60
mmHg and a respiration rate of 16 breaths/minute. Upon head and
neck exam, she had full ocular movements with no lid lag, retraction
or proptosis. Her thyroid was normal to palpation, with no lumps or
enlargement. There was a soft painless lymph node in her right
posterior cervical chain that measured under 1 cm. Auscultation of
her thyroid revealed no bruits. Nasal conchae look red and dry with
dried blood.

25 pmol/L. Neutrophils were reduced at 1.7x10 9/L. B12 was
decreased at 160 pmol/L.
0UV56ZDVGLDJQRVHGZLWKUHFXUUHQW*UDYHV¶GLVHDVHDQGVWDUWHGRQ
methimazole 5 mg daily. Her TSH, free T4 and free T3 will be
followed regularly. She was advised to return to her family doctor
for B12 injections and follow-up for her epistaxis, most likely due to
allergic rhinitis. Additionally, she was counseled to consult
optometry for her vision changes.
D ISC USSI O N
*UDYHV¶GLVHDVHLVLQFUHDVLQJLQSUHYDOHQFHDIIHFWLQJDERXWRI
Canadians, and more common in women than men.1 Thyroid
stimulating IgG antibodies (TSI) circulate in the body and activate
the thyrotropin receptor resulting in follicular hyperplasia and
hypertrophy.2 This enlarges the thyroid and increases thyroid
hormone (T3 and T4) production. Excess T3 and T4 work on the
pituitary, the heart, the liver, bone, reproductive organs, fat and
muscle resulting in manifestations of thyrotoxicosis, summarized in
Table 1.
'LDJQRVLVRI*UDYHV¶GLVHDVHFDQEHPDGHFOLQLFDOO\E\HYDOXDWLQJ
patients for hyperthyroidism signs and symptoms. Symptoms
include weight loss, heat intolerance, insomnia, tremor, increased
defecation, proximal muscle weakness, irritability, menstrual
irregularity and erectile dysfunction with decreased libido and
possible gynaecomastia in men.2 Signs include tachycardia,
³*UDYHV¶VWDUH´OLGODJSURSWRVLVJRLWHUUHVWLQJWUHPRU
hyperreflexia, warm and moist skin.2 Rarely, patients can present
with pretibial myxedema and thyroid-induced clubbing. Usually,
patients will report increased appetite and food intake with
paradoxical weight loss.
The case patient, Mrs. RS, did not present to clinic with overt
hyperthyroidism symptoms and only reported similar anxiety and
irritability that she experienced during her past thyroid problems.
Notably, the irritability was ³RXWRIKHUFRQWURO´DQGZDVVWDUWLQJWR
impact her home and work environments. Otherwise, her history and
SK\VLFDOZHUHZLWKLQQRUPDOSDUDPHWHUV7KLV³DSDWKHWLF
K\SHUWK\URLGLVP´LVPRUHW\SLFDOLQROGHUSDWLHQWVZKRSUHVHQWZLWK
weight loss or depression.2 Compared to younger patients, they are
less likely to exhibit tachycardia, tremor, goiter, exophthalmos or
increased appetite.3

Her lab results from her referral showed a TSH <0.05 mIU/L, free T4
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T able 1: T hyroid hor mone action and resulting manifestations of
thyrotoxicosis
System

A ction of thyroid
hormones

M anifestations of
thyrotoxicosis

Pituitary

Suppress TSH
production

Decreased TSH in labs

C ardiac

Increased channel
expression, increased ĮMHC and decreased ȕMHC expression,
increased serum atrial
natriuretic peptide

Increased heart rate and
contractility

Hepatic

Increased D1
deiodinase, LDL and
VLDL receptors, lipase,
and liver metabolism
enzymes

Increased peripheral T3
production, reduced
total cholesterol, LDL
cholesterol and
lipoprotein(a)

Skeletal

Increased osteocalcin,
alkaline phosphatase

Increased bone
turnover, osteopenia,
osteoporosis and
fractures

Reproductive

Male: increased sex
hormone globulin and
reduced free
testosterone
Female: antagonism of
estrogen action,
impaired gonadotropin
regulation

diagnRVLVRUPDQDJHPHQWRI*UDYHV¶GLVHDVH,Q*UDYHV¶SDWLHQWV
TSI antibodies would be present in the blood and the thyroid would
have elevated uptake of radioactive iodine homogeneously.2 As
such, with TSH <0.05 and free T4 elevated, the case patient RS has
*UDYHV¶GLVHDVH
7UHDWPHQWRI*UDYHV¶GLVHDVHLQFOXGHVWKUHHRSWLRQVDQWLWK\URLG
medications, radioactive iodine ablation and surgical management. 4
Antithyroid medications include the thionamides, propylthiouracil
(PTU) and methimazole (MMI), which inhibit thyroid peroxidase
and subsequent thyroid hormone synthesis.4 MMI is more effective
than PTU and with less adverse reactions even on higher doses.5
PTU is favoured during pregnancy as MMI is rarely associated with
teratogenicity: aplasia cutis and gastrointestinal defects.
Thionamides are generally started until patients are euthyroid, then
ZLWKGUDZQIRUUHPLVVLRQRI*UDYHV¶GLVHDVH+RZHYHUWKHHVWLPDWHG
UHFXUUHQFHUDWHRI*UDYHV¶RQWKLRQDPLGHVLVHVWLPDWHGWREH60%,4 as was in the case of Mrs. RS. Thionamide-induced
hypothyroidism correlates to a higher remission rate.6 Radioiodine
(I-131) ablation is used to induce hypothyroidism to prevent
UHFXUUHQFHVRI*UDYHV¶GLVHDVHDQGLVHIIHFWLYH/HDVWRIWHQ
surgical thyroidectomy can be used but is reserved for patients with
complications of antithyroid medication, those who decline
radioiodine and those with large goiters or thyroid nodules. 2 Total
thyroidectomy has similar complications as subtotal thyroidectomy,
however ST has a 30% recXUUHQFHUDWHIRU*UDYHV¶7 and thus total
thyroidectomy is preferred.8 Generally, in non-pregnant patients
ZLWKRXWKHSDWLFGLVHDVHWKHLQLWLDOWUHDWPHQWIRU*UDYHV¶GLVHDVHLV
MMI.

Male: erectile
dysfunction, decreased
libido

5HFXUUHQFHRI*UDYHV¶GLVHDVHLVWUHDWHGVLPLODUWRQDwYH*UDYHV¶
disease. However, some patients may need definitive treatment with
radioiodine or thyroidectomy. These patients are usually
hypothyroid post-treatment and are treated with L-thyroxine until
their TSH values are within normal parameters.

Female: irregular
menses

C O N C L USI O NS
*UDYHV¶GLVHase is a common problem presenting to family
physicians and endocrinology clinics. Despite the typical textbook
SUHVHQWDWLRQVRI*UDYHV¶GLVHDVHLQGLYLGXDOSDWLHQWV¶VLJQVDQG
symptoms are varied and one needs to seek context with laboratory
confirmation to make the diagnosis. Treatment is also individualized
to patient needs and can include antithyroid medication, radioiodine
(RAI) ablation or thyroidectomy. Recurrence rates are 50-60% with
antithyroid drugs, 20% in RAI ablation, 30% in subtotal
thyroidectomy and <1% in total thyroidectomy. Recurrences are
treated similarly to naïve disease. Recognition and treatment of
UHFXUUHQFHVRI*UDYHV¶GLVHDVHDUHLPSRUWDQWWRUHGXFHFRPSOLFDWLRQV
DQGLQFUHDVHSDWLHQWV¶TXDOLW\RIOLIH

M etabolic

Increased fatty acid
oxidation and sodiumpotassium ATPase

Increased
thermogenesis and
oxygen consumption

W hite fat

Increased adrenergic
lipolysis

Reduced fat mass

M uscle

Increased SERCA
activity, and serum
creatinine kinase

Proximal muscle
weakness, fatigue

$GDSWHGIURP%UHQW*$*UDYHV¶'LVHDVH1(QJO-0HG
358(24).

Resources for patients ZLWK*UDYHV¶GLVHDVH1DWLRQDO*UDYHV¶
Disease Foundation (www. Ngdf.org), the American Thyroid
Association (www.thyroid.org/patients/patients.html) and the
Thyroid Foundation of Canada (www.thyroid.ca).

  

,QYHVWLJDWLRQVWRFRQILUP*UDYHV¶GLVHDVHLQFOXGHVXSSUHVVHGVHUXP
TSH and elevated T3 and T4 levels. T3 OHYHOVLQ*UDYHV¶DUHHOHYDWHG
greater than T4 due to action of thyroid hormones on the liver
producing more D1-iodinases for peripheral conversion of T4 to T3.
Further testing for TSI antibodies and radioactive-uptake scans may
be useful in some patients; however, they are not necessary for
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$QDSSURDFKWRWKH³IORSS\FKLOG´FOLQLFDOO\
narrowing the differential diagnosis of
hypotonia in the pediatric population
6DUDK2¶&RQQRU 0HGV
Faculty Reviewer: Dr. R. Garth Smith MB, BS, FRCPC 'HSDUWPHQWRI3HGLDWULFV4XHHQ¶V8QLYHUVLW\
INTRODUC T ION
Hypotonia, defined as a reduced tension in a muscle at rest, is a
relatively frequent presentation in both the infantile and childhood
period. It must be differentiated from muscle weakness (a reduction
in muscle power, that may or may not accompany hypotonia), and
laxity (an increase in joint range of motion that often accompanies
hypotonia).
The possible causes of hypotonia in an infant or child are numerous,
and include problems with: the brain, the spinal cord, the peripheral
nerves, the neuromuscular junction, and skeletal muscles. The
clinical exam of the hypotonic infant or child will yield many clues
that the astute physician (or medical student) may use to narrow this
broad differential diagnosis and to focus subsequent investigations.
This case report will allow the student to develop an approach to
hypotonia in the pediatric population.
C ASE
MS is a 2 year old boy who initially presented to his family physician
at approximately 18 months when his parents noticed he was walking
with his IHHWWXUQHGRXWDQGWKDWKHGLVSOD\HGD³ZDGGOLQJJDLW´$W
the time, the parents mentioned that their son had difficulty keeping
up with other children when walking, and would frequently trip when
running. MS was subsequently referred to a general pediatrician,
who noted proximal muscle wasting in the lower extremities, and
calf hypertrophy bilaterally. MS was also described as exhibiting a
SRVLWLYH³*RZHUVLJQ´$UHIHUUDOZDVPDGHWRDQRUWKRSHGLF
surgeon, and X-rays of the lower limbs revealed no bony
abnormalities. Upon consultation with neurology, the patient was
admitted to Kingston General Hospital (KGH), and several
diagnostic investigations were performed. The results of these
investigations lead to a definitive diagnosis and a referral was made
to the Child Development Centre (CDC) in Kingston, ON for followup care. To encourage reader involvement in formulating a
GLIIHUHQWLDOGLDJQRVLVIRUWKLVFDVH06¶VGLDJQRVLVZLOOQRWEH
revealed until the end of this article.
MS presented with his parents in consultation at the CDC at the age
of 2 years and 1 month. Past medical history revealed a complicated
pregnancy, with his mother having a serious kidney infection
requiring hospitalization at 36 weeks. At birth, there was meconium
staining of the amniotic fluid, and MS required suctioning and inhospital observation for 4-5 days. He initially had trouble feeding
(would gag for the first few days), but subsequently, his mom
reported no history of gagging, choking, or trouble swallowing.
Functionally, MS is currently able to eat with a fork and spoon,
although his mother has noticed a tremor in his hand at times. He is
progressing well with regards to language development, with a large

vocabulary, and saying several two-to-three word sentences.
Adaptively, he is able to feed himself, and is showing interest in
being toilet-trained.
Physical examination revealed a pleasant, engaging young boy who
was very cooperative with most aspects of the exam. He tended to
SUHIHUHQWLDOO\VLWLQD³:-posture´IRUHQKDQFHGVWDELOLW\+LVJDLWLV
waddling and shows a wide-based stance. He likes to climb,
although he has difficulty, and will often pull on the edge of his
shorts to lift his legs up and over obstacles. MS demonstrates a
SRVLWLYH³*RZHUVLJQ´ZKen getting up from the ground. His tone is
decreased and there is significant hypermobility of all joints. Deep
tendon reflexes (DTRs) are absent in the lower limbs bilaterally.
Proximal muscle weakness is present both in the upper limbs
(difficulty throwing a ball over his head), and the lower limbs (will
tug on his shorts when performing a seated leg raise to kick at a ball).
MS has functional fine motor skills that allow him to participate in a
variety of activities. He uses a mature pincer grasp for picking up
small objects, and uses an age-appropriate grasp when holding a
marker. MS does have a noticeable tremor when completing
activities requiring fine precision.
D ISC USSI O N
This section of the article will aid the student in developing and
narrowing the differential diagnosis for the presented case.

Distinguishing upper motor neuron disorders from lower motor
neuron disorders
The upper motor neurons (UMN) originate in the motor cortex of the
brain and carry motor information to the spinal cord. Pediatric
disorders of the UMN (characterized by hypertonia, increased DTRs,
presence of the Babinski reflex, and an absence of muscle atrophy)
include certain types of cerebral palsy, and chromosomal
abnormalities (Table 1).
The lower motor neuron (LMN) carries motor information from the
brainstem or spinal cord out to the skeletal muscles. LMN disorders
are characterized by hypotonia, muscle weakness and possible
atrophy, and reduced or absent DTRs (Table 1).
Examining MS revealed a boy with hypotonia, muscle weakness, and
absent DTRs, consistent with the presentation of a LMN disorder.
Once the disorder has been identified to affect the LMN, the
physician must further narrow the differential diagnosis by
determining the portion of the LMN that is affected.

Distinguishing between different LMN disorders
The LMN is composed of the anterior horn cell of the spinal cord,
the peripheral nerve, the neuromuscular junction, and the skeletal   
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muscle. An LMN disorder may affect any or all of the above
components. Again, clinical examination will often identify the
affected area.

R E F E R E N C ES
1.

Recall that MS presented with proximal muscle weakness, absent
DTRs, and intact sensation. Consulting Table 2 indicates that this
pattern is consistent with either an anterior horn cell disease, or
possibly with a muscular disease.

2.
3.

Diagnosis
Investigations at KGH revealed a normal creatine kinase (CK) level,
UXOLQJRXWWKHSRVVLELOLW\RI'XFKHQQH¶VPXVFXODUG\VWURSK\
(DMD).1 Subsequent EMG studies revealed normal functioning of
the lower limb motor units, suggesting a neurogenic cause of the
hypotonia and weakness. Genetic testing was done and was positive
for spinal muscle atrophy (SMA).
SMA is an inherited degenerative neuromuscular disorder with a
birth incidence of approximately 1 in 10,000.2 It affects the anterior
horn cells of the spinal cord and can be clinically separated into four
classes based on age at onset and developmental milestones achieved
(Table 3). Based on his presentation, it is likely that MS has Type
IIIa SMA, although further monitoring is required to confirm this.
There is no known effective treatment for SMA. Patients receive
supportive care to manage symptoms and prevent complications such
as scoliosis and joint contractures.3,4 The prognosis varies
considerably depending on SMA type and age at onset.5,6 MS will be
followed every six months by the neuromuscular team at the CDC.

4.

5.
6.

Rosalki, SB. Serum enzymes in diseases of skeletal muscle.
Clin Lab Med. 1989 Dec;9(4):767-81.
Wong M, Percy M. Spinal muscular atrophy: an inherited
neuromuscular disorder with a potentially optimistic future. J
on Dev Disabil. 2009; 15(3):103-117.
Burnett BG, Crawford TO, Summer CJ. Emerging treatment
options for spinal muscular atrophy. Curr Treat Options
Neurol. 2009 Mar;11(2):90-101.
Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A,
Wong B, Aloysius A, Morrison L, Main M, Crawford TO,
Trela, Participants of the International Conference on SMA
Standard of Care. Consensus statement for standard of care in
spinal muscular atrophy. J Child Neurol. 2007
Aug;22(8):1027-49.
Ignatius J. The natural history of severe spinal muscular
atrophy²further evidence for clinical subtypes. Neuromuscul
Disord. 1994 Sep-Nov;4(5-6):527-8.
Zerres K, Rudnik-Schonebom S, Forrest E, Lusakowska A,
Borkowska J, Hausmanowa-Petrusewicz I. A collaborative
study on the natural history of childhood and juvenile onset
proximal spinal muscular atrophy. J Neurol Sci. 1997 Feb
27;146(1):67-72.

  

C O N C L USI O N
This case illustrates the importance of a thorough history and
physical exam in the diagnosis of neuromuscular disorders in the
hypotonic infant or child. Through careful deduction, the prudent
physician or student can arrive at a narrow differential diagnosis,
eliminating the need for unnecessary diagnostic testing, which is of
benefit to both young patients and their families.
T able 1: Clinical Distinction between Upper Motor Neuron and
Lower Motor Neuron Lesions
Upper Motor
Lower Motor
Neuron
Neuron
C linical Sign
(Neuromuscular)
(Corticospinal
T ract)
Tone

Increased (spastic)

Decreased

Reflexes

Increased

Decreased

Babinski reflex

Present

Absent

A trophy

Absent

Possible

F asciculations

Absent

Possible

From Lewis DW. Neurology. In Marcdante KJ, Kliegman RM,
Jenson HB, Behrman RE (eds). Nelson Essentials of Pediatrics, 6th
ed. Philadelphia, Saunders, 2011.
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T able 2: Peripheral nervous system disorders

T ypical F indings
Sensory

Location of L esion

Motor

Deep
Tendon
Reflexes
Ļ

([DPSOHVRI&DXVH

A nterior Horn C ell

Weakness and atrophy in a
segmental or focal pattern;
fasciculations

Sensation intact

Spinal Roots and
Nerves

Weakness and atrophy in a rootinnervated pattern; sometimes
with fasciculations

Corresponding
dermatomal sensory
deficits

Ļ

Transverse myelitis,
herniated cervical or
lumbar disc

Peripheral Nerve²
Mononeuropathy

Weakness and atrophy in a
peripheral nerve distribution;
sometimes with fasciculations

Sensory loss in the
pattern of that nerve

Ļ

Trauma

Peripheral Nerve²
Polyneu-ropathy

Weakness and atrophy more
distal than proximal; sometimes
with fasciculations

Sensory deficits,
commonly in stockingglove distribution

Ļ

Neuromuscular
Junction
M uscle

Fatigability more than weakness

Sensation intact

Normal

Weakness usually more
proximal than distal;
fasciculations rare

Sensation intact

1RUPDORUĻ

Hereditary: CharcotMarie-Tooth disease
Acquired: GuillainBarré syndrome
Infantile botulism,
myasthenia gravis
Muscular dystrophy

Spinal muscular
atrophy, polio

  
 Note: disease examples altered from original source to apply to pediatric population.
Adapted from Bickley LS, Szilagyi PG: Ba WHV¶*XLGHWR3K\VLFDO([DPLQDWLRQDQG+LVWRU\7DNLQJ, 10th ed. Philadelphia,
Lippincott Williams & Wilkins, 2009.  

  
T able 3: Classification on infantile SMA
SM A type
I (Werdnig-Hoffmann)

Definition
Onset < 6 months, never sat

II (intermediate)

18 months, sits and stands with support,
unaided walking not achieved
IIIa < 3 years, walks with early
difficulties
IIIb 3 ± 30 years, normal motor
development

III (Kugelberg-Welander)

Prognosis
Death usually within the first years of
life, chronic courses in about 10 %
Survival mostly into adulthood.
Lifespan generally not reduced, variable
ambulatory period

  
From Rudnik-Schoneborn S, Hausmanowa-Petrusewicz I, Borkowska J, Zerres K: The predictive value of achieved motor
milestones assessed in 441 patients with infantile spinal muscular atrophy types II and III. Eur Neurol 45:174-181, 2001.
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Approach to treatment decision making in an
aggressive case of pediatric multiple sclerosis
Lauren Sham (Meds 2014)
Faculty Advisor: Dr. Brenda Banwell MD, FRCPC (Department of Pediatric Neurology, Hospital for Sick Children)

C ASE
A 13 year old previously well female presented in April 2011 with
nausea, vertigo, mild gait ataxia, diplopia and fatigue. Her initial
MRI (Figure 1) showed more than 20 hyperintense lesions on T2
FLAIR that were >3 mm in size throughout the supratenetorial white
matter, with multiple lesions in periventricular and corpus callosal
areas. Contrast enhancing lesions were found in the right frontal lobe
subcortical white matter, projecting from the corpus callosum, in the
optic chiasm and superior cerebellar peduncle. Multiple T1
hypointense black holes were also found. MRI features met
McDonald 2010 criteria for multiple sclerosis (MS). Spinal fluid was
positive for oligoclonal bands. She was treated with a 5 day course of
IV solumedrol then prednisone at 50 mg/d at 10 day taper. The
family was counseled for high risk of recurrent symptoms and
diagnosis of MS. At the end of her course of IV steroids she had a
near full neurological recovery with some mild residual sensory
deficits.
In May 2011, she began to experience left sided numbness below her
QHFNDQGGRZQKHUOHJDQGH[KLELWHGDSRVLWLYH/¶+HUPLWWH¶VVLJQ D
classic finding in MS: an electrical sensation running down the back,
often elicited by bending the head forward). These new neurological
symptoms localizing to the spinal cord were distinct from her initial
presentation, which was more than 30 days previous to this attack.
This allowed further confirmation of MS diagnosis using Poser
clinical criteria. Steroid treatment was not initiated as the patient did
not find these sensory symptoms bothersome. The MRI at this point
showed some lesions decreased in size, and one new gadolinium
enhancing lesion indicative of active inflammation. Follow up MRIs
in July and August 2011 showed multiple new hyperintense lesions
in the brain and spinal cord including the brainstem, some of which
were gadolinium enhancing, and some older lesions increased in size.
D O ES SH E H A V E MS?
There have been several iterations of the diagnostic criteria for MS.
This patient meets Poser Criteria for MS:1 two attacks and clinical
evidence of two separate lesions involving different parts of the CNS
separated by a period of at least one month, and each lasting a
minimum of 24 hours. She also meets McDonald 2005 Criteria:2
demonstrates two or more attacks and objective clinical evidence of
two or more lesions (shows dissemination in space: two or more
MRI-detected lesions consistent with MS, dissemination in time: two
separate clinical attacks). Her initial MRI also met the 2005 criteria
for lesion dissemination in space (3 of: (i) >9 T2 lesions, >3
periventricular lesions, >1 juxtacortical lesion or (iv) >1
infratentorial lesion). As well, her baseline MRI also met the newer

F igure 1: Axial and sagital T2 FLAIR images showing
periventricular, corpus callosal, and juxtacortical white matter
lesions.
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McDonald 2010 Criteria:3 dissemination in space (>1 T2 lesion in at
least 2 of 4 areas of CNS (periventricular, juxtacortical,
infratentorial, spinal cord)) and dissemination in time (simultaneous
presence of asymptomatic gadolinium-enhancing and nonenhancing
lesions). CSF oligoclonal bands were present ± a finding noted in
92% of pediatric MS patients.4 Investigations excluded other
conditions. Thus, by all criteria, she has a diagnosis of MS. Pediatric
MS represents up to 10% of all cases and is characterized by a
relapsing-remitting course (RRMS).
SH O U L D T R E A T M E N T B E IN I T I A T E D?
This decision can be made based on predictors of poor outcome in
MS, as well as the natural history of the untreated disease. Based on
data from RRMS in adults (as limited studies have been done in
children), it has been found that early disease outcomes such as a)
incomplete recovery from first attack and b) shorter time to second
attack are strong predictors of poor prognosis and future disability
(reviewed in 5), both of which this patient exhibits. The natural
course of RRMS, if untreated, is as follows: in 10 years, 30-50% of
patients require walking aids, and in 30 years, up to 80% require
walking aids, and up to 30% are restricted to their bed with effective
use of only their arms.6 Due to the certainty of her diagnosis, and
likelihood of future disability, this patient would be counseled to
consider treatment.
C H O I C ES F O R L O N G T E R M T R E A T M E N T
Currently there is no cure for MS. Long-term treatment encompasses
first and second-line therapies (reviewed in 7, 8).

Second line therapy
Second line MS therapy includes cyclophosphamide and
natalizumab. Cyclophosphamide acts to induce a general state of
immunosuppression. Its mechanism is presumably through
lymphocytotoxicity and decreasing lymphocyte subsets (reviewed in
8). It is used in adult patients with severe active MS, and a
retrospective study in pediatric patients with severe MS revealed a
reduction in the mean annualized relapse rate, although 75% of
patients acquired new lesions on MRI over 12-24 months of
treatment.12 The risk of infertility, infection and long-term
malignancy increases with total dose and strategies for fertility
preservation should be considered (reviewed in 8). It is an option for
aggressive MS refractory to first-line therapies.
Natalizumab (Tysabri) inhibits VLA4 through binding to a subunit of
ĮȕLQWHJULQLQKLELWLQJO\PSKRF\WHPLJUDWLRQDFURVVEORRGEUDLQ
barrier and also resulting in T-cell apoptosis. In adult MS trials, it has
been shown to decrease relapse rates by 68% and reduce the
formation of new enhancing lesions by >90% relative to placebo.13
Open label case series in adolescents described a marked relapse-rate
reduction and favorable safety profile (reviewed in 8). However, it
has been associated with increased risk of opportunistic infection. Of
particular concern, Tysabri has been associated with a 1/1000
incidence of active infection with JC virus, leading to progressive
multifocal leukoencephalopathy (PML), an infection almost
exclusively associated with immunosuppressed patients including
AIDS. Careful monitoring strategies including prior determination of
JC virus serology are now in place and protocols for treatment of
PML are being optimized (reviewed in 14). Nonetheless, PML is a
major deterrent for widespread use of Tysabri.
T W O M O D E LS O F C A R E

F irst line therapy: Immunomodulation
First line therapy for MS includes iQWHUIHURQȕ 5HELI$YRQH[
Betaseron) and glatiramer acetate (Copaxone). The clinical benefit of
LQWHUIHURQȕLVWKRXJKWWREHPHGLDWHGWKURXJKVHYHUDOPHFKDQLVPV
inhibition of proinflammatory cytokines, induction of antiinflammatory mediators, reduction of lymphocyte migration across
the blood brain barrier, and inhibition of T-cell activation, among
others. In Phase III pivotal trials in adult MS, interferon treatment
demonstrated a 30% reduction in relapse rate compared with placebo
for periods of 2-3 years.9 Formal trials have yet to include patients
under 18 years old, but retrospective reviews show benefit and
suggest safety and tolerability (reviewed in 7, 8).
Glatiramer acetate is an acetate salt mixture of synthetic polypeptides
designed to mimic human myelin basic protein (MBP). It is
postulated to induce regulatory and/or suppressor T cells, shift T
helper response from TH1 to TH2, and shift antigen presenting cell
function to type II. It was found to reduce number of relapses by
29% in adults with RRMS over 2 years.10 Studies in children are
limited but it seems to be effective (reviewed in 8).
First-line treatment failure can occur due to inadequate effectiveness
(failure to reduce relapse rate), intolerable adverse effects or
presence of unacceptable level of breakthrough disease (severity or
frequency of attacks).8 It is difficult to define treatment failure and
consensus criteria for children have not been established. However,
one paper showed that 1/4 of children experience breakthrough
disease and switched to second-line therapy an average of 1.5 years
after starting first-line therapy.11

The nature of MS as a chronic disease and its onset in childhood lend
careful consideration to the intensity of initial therapy. Two potential
models of care (as discussed in 8 FDQEHFRQVLGHUHG µ6WDUWORZ
DQGHVFDODWHLIQHFHVVDU\¶DQG µ6WDUWVWURQJDQGPDLQWDLQ¶
Approach #1 is currently the standard of practice for most pediatric
MS patients. It emphasizes greater safety with reduced potency and
may be valuable to consider in multiple sclerosis, a disease with
lifelong exposure to medication. Approach #2 involves powerful
immunosuppression followed by maintenance of remission by less
potent medications, which is similar to care of pediatric patients with
severe rheumatological disease. It is considered for newer therapies
and more aggressive disease, as it provides greater early disease
suppression, which is important to consider in the context of limiting
inflammation-mediated brain injury in the context of a developing
pediatric CNS. However, it carries greater risk of toxicity, significant
risk of opportunistic infection (e.g. PML in the case of Tysabri) and
consideration of potentially life-altering decisions (e.g. fertility
implications in the case of cyclophosphamide), which is especially
pertinent in the care of pediatric patients. In this case of our patient:
should the treatment decision reflect the current standard of care for
pediatric MS patients or does her highly aggressive disease indicate
that second line therapy should be pursued?
E PI L O G U E
The family decided to pursue cyclophosphamide as their choice of
treatment. Though the role of the physician is to guide patients and
their families towards appropriate treatment, it is pertinent to keep in
mind that the family has the final decision.
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Nodular regenerative hyperplasia of the liver
presenting with ascites in a woman with
limited systemic sclerosis
Arielle Mendel (Meds 2013)
Faculty Reviewer: Dr. Lori Albert MD, FRCPC (Division of Rheumatology, Toronto Western Hospital, University
of Toronto)
C ASE
A 57-year old Caucasian female was being followed for a 30-year
history of limited systemic sclerosis. Her disease first presented with
5D\QDXG¶VSKHQRPHQRQLQDQGVKHVXEVHTXHQWO\GHYHORSHG
digital calcinosis, dysphagia and esophageal reflux, sclerodactyly,
and widespread telangiectasia.
In 2003, she developed progressive dyspnea on exertion
accompanied by chest tightness and a single episode of syncope.
Physical examination was significant for a split S2 with a loud
pulmonic component. Pulmonary function testing showed a
decreased diffusion capacity. RSVP was found to be elevated on
2D-Echocardiogram. These findings supported a diagnosis of
pulmonary arterial hypertension (PAH) secondary to scleroderma.
She received continuous IV prostacyclin infusion in combination
with an oral prostacyclin analogue. Sildenafil was added in 2007,
due to worsening exercise tolerance. She underwent evaluation for
lung transplantation, but a decision was reached to defer the
procedure unless her status worsened further.
In 2007, the patient began to experience intermittent episodes of dull
and diffuse RUQ pain. Her abdomen was noted to be protuberant on
several occasions. However, repeated laboratory tests and imaging
of abdomen and liver remained normal. An upper GI endoscopy was
performed in 2008 and showed no significant abnormalities.
In June of 2011 she presented to the ER with increasing RUQ pain,
abdominal fullness, and weight gain of 10 lbs despite decreasing
appetite over the last 2-3 months. There was no icterus or pedal
edema. AST and ALP were mildly elevated (45 IU/L and 161 IU/L
respectively), with normal albumin and INR. Abdominal ultrasound
showed ascites, splenomegaly and bilateral pleural effusions, and she
was admitted to hospital for further evaluation. Paracentesis
revealed a serum-to-ascites albumin gradient of 11 with no evidence
of infection. Hepatic venous pressure gradient was at the upper limit
of normal (5 mmHg). Gastroscopy showed marked portal
hypertensive gastropathy with no significant varices. Cardiac RVSP
was measured at 96 mmHg (N<40 mmHg) on 2D-echocardiogram,
which had remained stable at this level for the past few years.
A transjugular liver needle biopsy was then performed. This
revealed loss of small portal veins and nodularity of the hepatic
parenchyma with minimal fibrosis, no fibrous septa and no evidence
of cirrhosis or other disease. Of note, bile ducts were present in
normal numbers and appeared normal, with no observed cholestasis.
These histological changes were diagnostic for Nodular Regenerative
Hyperplasia (NRH) of the liver.
The treating physicians felt that this SDWLHQW¶VSUHVHQWDWLRQRI584
pain with ascites was the result of non-cirrhotic portal hypertension

  

secondary to NRH, which was further exacerbated by severe PAH.
The patient was treated with gentle diuresis and supportive
management, and over the course of her admission her ascites
diminished moderately and pleural effusions resolved. It was
recognized that aggressive dieresis, therapeutic paracentesis or a
transjugular intrahepatic portosystemic shunt (TIPS) procedure were
all contraindicated given her fragile cardio-pulmonary status
secondary to PAH. She was discharged after two weeks on
spironolactone, a no added salt diet, and continued close monitoring
of fluid balance. Unfortunately, this complication of her disease will
limit her suitability for future lung transplantation.
D ISC USSI O N
Systemic sclerosis (SSc) or scleroderma is a rare disease
characterized by progressive fibrosis of cutaneous, vascular and/or
visceral connective tissue.1 The pathogenesis is linked to sustained
immune-mediated activation of fibroblasts and endothelial cells.2
7KHµOLPLWHG¶RUµGLIIXVH¶VXEW\SHVRI66FGLIIHUZLWKUHVSHFWWRWKH
extent of skin fibrosis, organ involvement, antibody production, and
survival.1,3 Features of limited SSc (l-SSc) include the CREST
syndrome (calcinosis cutis5D\QDXG¶VSKHQRPHQRQHVRSKDJHDO
dysmotility, sclerodactyly, telangiectasia) and anti-centromere
antibodies.4 Patients with either subtype require continuous
monitoring for specific organ complications, and supportive
treatment targeted towards affected tissues.
Nodular regenerative hyperplasia (NRH) is a pathological description
for abnormal regenerative nodules within the hepatic parenchyma in
the absence of fibrosis.5 NRH is rare diagnosis, known to develop in
the context of autoimmune, hematologic and malignant disorders as
well as certain drug exposures.5 In a case series of 42 patients with
NRH, one quarter had an underlying rheumatologic disorder6, and a
recent review found 7 reports of NRH associated with SSc or CREST
syndrome.5
The regenerative nodules in NRH are thought to be a reactive process
of hepatocytes secondary to disrupted vascular flow.5 Clinically,
NRH belongs to a heterogeneous group of disorders causing noncirrhotic portal hypertension, characterized by elevated portal
pressures, ascites, or varices in the absence of cirrhosis or significant
liver dysfunction.7,8 The pathogenesis of non-cirrhotic portal
hypertension likely involves pre-sinusoidal and portal vessel injury,
fibrosis, and thrombosis.5,7 The chronic inflammation, autoantibodies, and pro-thrombotic state present in rheumatic diseases
may precipitate this process.6,9 In SSc, the abnormal fibroblast
activity responsible for cutaneous thickening may also be present in
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the portal tracts.10
11

Although non-specific liver abnormalities are common in SSc ,
intrinsic liver disease is seen infrequently.12 Primary Biliary
Cirrhosis (PBC), involving progressive obliteration and fibrosis of
intrahepatic bile ducts, is the liver disease most commonly associated
with l-SSc.9,11,13 Conversely, NRH is a very rare complication12,14,
and only case reports exist in the literature.5 Interestingly, NRH has
been reported as an overlap syndrome with PBC in patients with
CREST.15,16 In this patient, a minimally elevated ALP in the
presence of normal bile ducts in the biopsy specimen makes a
diagnosis of overlapping PBC unlikely.15
NRH should be considered in the context of preserved liver function,
minimally elevated liver enzymes, and no evidence of cirrhosis. 5
The diagnostic gold standard for NRH is liver biopsy14; imaging and
other non-invasive tests are less helpful diagnostically.5,17
Management consists of treating the underlying condition(s) and
preventing or treating portal hypertension, as these are the main
prognostic factors in this condition.5,6
Portal hypertension will eventually develop in 50% of patients with
NRH, but it is uncommon for manifestations such as ascites to be
present at the time of diagnosis.6,15 One of the factors that likely
FRQWULEXWHGWRWKLVSDWLHQW¶VGUDPDWLFSUHVHQWDWLRQZDVKHUORQJstanding pulmonary arterial hypertension (PAH), which is estimated
to affect 10-25% of SSc patients.18 Prostacyclin analogues,
endothelin-receptor antagonists and PDE-5 inhibitors have been
shown to improve function and delay progression in patients with
PAH-SSc19,20, but it remains the leading cause of mortality in
patients with l-SSc.18 Interestingly, there have been numerous
reports of NRH co-existing with PAH in patients with SSc and other
diseases, suggesting that a common vascular pathogenesis may
underlie these conditions.5,15,21,22 Alternatively, PAH may be
responsible for producing the circulatory disturbance that initiates the
development of NRH.22
This is an example of a rare condition, Nodular Regenerative
Hyperplasia of the Liver, presenting in a relatively rare disease,
scleroderma. The initially subtle signs and lack of laboratory
abnormalities further confounded efforts to identify the underlying
problem. Our patient had a prolonged stay in hospital, and the ability
to make the diagnosis and provide appropriate care required the
collaboration with, and expertise of hepatologists, gastroenterologists
and respirologists. This case highlights the need for
multidisciplinary management of patients with complex rheumatic
disorder, particularly in the setting of diagnostic and therapeutic
dilemmas. Further research is warranted to investigate the
relationship between pulmonary hypertension and the vascular
pathogenesis of NRH.
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Gastric Schwannoma: a rare Schwann cell
tumour of the GI tract
Mark Xu (Meds 2014)
Faculty Reviewer: Dr. Steven Latosinsky MD, MSc, FRCSC (Department of General Surgery, Victoria Hospital,
LHSC)

Schwannomas are benign, slow-growing, encapsulated nerve-sheath
tumors arising from Schwann cells, which are responsible for the
myelin sheath in the peripheral nervous system.1 Schwannomas are
most commonly found in the cranial vault, involving the myelinforming cells of the 8th cranial nerve, in a condition called vestibular
neuroma.2 In rare cases, they can also occur in the GI tract, usually in
the stomach.3 GI schwannomas are often non-encapsulated, but well
demarcated.4
Gastric schwannomas account for only 0.2% of all gastric tumors and
4% of all benign gastric neoplasms.5 The peak incidence is in the 4th
and 5th decade of life, usually involving females.5,6 They can also
occur in children, and can be malignant in rare cases.7 The majority
of patients have remained asymptomatic for extended periods of
time, with most cases discovered incidentally on imaging or
laparotomy.5,8 Symptomatic patients most often present with
ulcerations and upper GI bleeding, and a palpable mass may be
present if the tumor grows exophytically.5 Malignant transformations
are exceedingly rare, but have been reported.9
C ASE
The patient is a 34-year-old female who presented to the ER with
RLQ pain and lower back pain persisting for the past 10 days. Her
vital signs were stable with a normal white cell count.
CT-scan of her abdomen showed a normal appearing appendix. Fluid
was seen in the pelvis, possibly secondary to a ruptured ovarian cyst.
There was an incidental finding of a mass that appeared to be arising
from the stomach. The mass appeared intramural and measured 5.1
cm x 4.4 cm. An ultrasound was done to look at lesions in the liver
which were felt to be hemangiomas.
7KHSDWLHQW¶VSDLQZDVVRPHZKDWFRQWUROOHGZLWKPRUSKLQHDOWKRXJK
it was still present. No cause of pain was determined. She was
discharged from the emergency department with Percocet and
scheduled to return for an esophagogastroduodenoscopy (EGD)
approximately 4 weeks later.
8SRQUHWXUQIRUWKH(*'WKHSDWLHQW¶VSDLQZDVPXFKLPSURYHGDQG
she discontinued all her pain medications. The EGD showed a
submucosal mass 5 cm below the gastroesophageal junction. The
patient was referred to GI to for endoscopic ultrasound (EUS).
When seen by GI one month later, the patient revealed a prior history
of anxiety disorder and was being treated with Paxil. She also had
constitutional symptoms of anorexia and reported a 45-pound weight
loss. An upper endoscopy was performed and the gastric mass was
visualized along the lesser curvature of the stomach. The mass felt
firm when probed.

F igure 1. Abdominal CT scan showing LUQ mass.
On endoscopic ultrasound, the mass appeared hypoechoic but had
evidence of hyperechogenicity foci. It measured 5.2 cm x 3.3 cm in
its largest dimensions and was well demarcated, originating from the
muscularis propia of the stomach. There was evidence of a
perigastric lymph node as well as two celiac lymph nodes. A fine
needle aspiration (FNA) for cytology as well as a core biopsy for
histopathology was performed on the primary mass and one of the
nodes. The mass was not endoscopically resectable.
Microscopic evaluation of lesion cells revealed a palisaded growth
configuration, with elongated spindled nuclei and pointed ends. No
mitosis or necrosis was seen. Immunochemistry was positive for S100; negative for CD117, CD34, desmin, muscle specific actin and
caldesmon. These findings were consistent with a diagnosis of
schwannoma.
An ultrasound was done approximately 6 months later to reassess the
mass, which appeared unchanged. She is currently being followed
with annual CT-scans; no surgery is planned.
D ISC USSI O N
This is an interesting case of a gastric mass found incidentally for the
presentation of right lower quadrant pain.
Briefly, the presenting pain was relatively severe and never
explained. Appendicitis is the most likely cause of acute RLQ pain,10
EXW RXUSDWLHQWV¶ DSSHQGL[ DSSHDUHG QRUPDO RQ &7-scan. There was
also suspicion of a ruptured ovarian cyst based on fluid seen in the
pelvis on ultrasound. However, the ovaries were normal and this
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GLDJQRVLV ZDV VRPHZKDW LQFRQVLVWHQW ZLWK WKH SDWLHQW¶V -day
history of pain: fluid from an uncomplicated ruptured ovarian cyst is
normally reabsorbed in 24 hours, with the pain resolving in a few
days.11 The pain did resolve, and further investigations focused on
the incidental gastric mass.

be reserved for either malignancy or for symptomatic cases,
especially for difficult operations such as in our patient. Most of the
literature on surgical outcome appears to be based on cases were
diagnosed as schwannomas post-operatively; therefore, the benefits
of surgery for known asymptomatic cases are unclear.

The differential diagnosis of a submucosal gastric mass is broad and
includes gastrointestinal stromal tumor (GIST), leiomyoma,
leimyosarcoma, and schwannoma, among others.12 Upper endoscopy
is useful in examining epithelial tumors; however, it is inadequate for
examining tumors below the mucosa.13 In contrast, EUS is effective
in visualizing submucosal tissue adjacent to the gastric wall and can
be used to precisely guide needle biopsies.13

Taking into account the available information, we felt that it was best
to follow our patient with annual CT-scans, and to defer any surgical
intervention until her symptoms become unmanageable; or until the
improbable event that her tumor becomes malignant.

It is important to differentiate between gastric schwannomas and
other mesenchymal tumors, particularly the main differential of
GIST, which has a higher chance of being malignant. The diagnosis
of a GIST would mandate surgical resection if possible. Imatinab is
used both as an adjuvant therapy when the GIST is completely
excised and palliatively for unresectable or metastatic disease.1,14,15
It was found that virtually all cases of GIST would exhibit malignant
behavior if followed, and metastatic cases can be effectively treated
with imatinib mesylate, which improves survival from <50% to
>90% at 1 year.14,15 In comparison, schwannomas remain benign in
nearly all cases, and are rarely symptomatic.5 As the tumor enlarges,
it displaces the nerve to the periphery, preserving its function.16
Symptoms can result from the enlarging submucosal tumor
restricting circulation to the mucosa, leaving it ischemic and prone to
ulceration, bleeding, and damage by gastric acidity.17

1.

Imaging modalities such as CT, ultrasound, and MRI can provide
limited but useful information. Schwannomas often appear uniform
on CT, which can distinguish it from leiomyomas and
leiomyosarcomas; ultrasound with a sufficient resolution can
GHWHUPLQHWKHWXPRU¶VOD\HUVRIRULJLQDQG05,FDQPDSWKHSUHFLVH
location of the tumor and the displacement of its surrounding
organs.18,19,20 These findings may also be helpful in explaining the
cause of symptoms as well as determining the best approach to
treatment, particularly in surgical cases.
Due to the similar spindle-shaped appearance of schwannomas and
other gastric mesenchymal tumors, it can be difficult to distinguish
between them using light microscopy.21 Grossly, they resemble
leiomyomas and other stromal tumors: solitary, firm, smooth, whiteish in color, and well circumscribed.5 Advances in
immunohistochemistry allowed for a more precise differentiation: in
one study, 24 out of 306 gastric spindle-cell tumors were diagnosed
as schwannomas using immunohistochemistry, but only 9 were
diagnosed as schwannomas using hematoxylin-eosin.22
Immunohistochemical diagnosis of schwannoma is based on
positivity for the S-100 protein, and negativity for CD117, CD34,
desmin, and muscle specific actin.23 CD117 and CD34 are positive in
GIST, and muscle specific proteins such as actin, desmin, and
caldesmon are positive in smooth muscle tumors such as leiomyoma
and leiomyosarcoma; all of which are negative in schwannomas.23
Our patient¶s results are congruent with this guideline and a
definitive diagnosis of schwannoma can be made.
Surgical treatment for gastric schwannomas would involve complete
resection of the tumor.24 For our patient, this would mean a
gastrectomy: the complete or partial excision of the stomach. The
post-operative prognosis is excellent5,1 and most patients return to
their pre-operative quality of life;25,26 however, it is debatable
whether or not surgery should be deemed necessary for benign,
asymptomatic schwannoma patients. In our opinion, surgery should
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Diabetic Foot Syndrome in a Middle Aged Male
with Complicated Type II Diabetes
Jeffrey M. Landreville (Meds 2014)
Faculty Reviewer: Dr. Heather Percival MD, CCFP (Department of Family Medicine, Seaforth Community
Hospital)

Diabetes mellitus (Diabetes) represents a group of metabolic
disorders characterized by elevated plasma glucose levels and
abnormal insulin activity within the body. Diabetes can be further
classified into Type 1 (T1DM) and Type 2 (T2DM). T1DM is
caused by an autoimmune failure of the beta cells in the pancreas
leading to the complete absence of insulin in the body. In T2DM,
hyperglycemia stems from a combination of insulin resistance,
insulin deficiency and abnormal glucagon synthesis.1

Clindamycin 600 mg tid) and strict bed rest. On admission the
patient was afebrile with a WBC of 5.4 x10 9/L (normal 4-10).
)ROORZLQJWZRGD\VRIWUHDWPHQWWKHLQIODPPDWLRQLQ0U'¶VIRRW
appeared markedly decreased and he was discharged from hospital
on the third day. A follow-up physical exam by his primary care
physician revealed the left foot to be completely absent of any signs
of infection.

The number of individuals with diabetes has been increasing at an
alarming rate. In 2000, the worldwide prevalence of diabetes was
estimated to be over 150 million. It is projected that in 2025 this
number will reach 380 million.2 Within Canada, it is projected that
2.4 million Canadians will have diabetes by the year 2016. 3

D ISC USSI O N

Diabetes is a serious condition that can lead to a wide variety of life
threatening macrovascular (coronary artery disease, peripheral
arterial disease, stroke) and microvascular (nephropathy, neuropathy,
retinopathy) complications.4 The constellation of lower limb
complications associated with diabetes such as ulcers and infections
can be referred to as a diabetic foot syndrome (DFS).5 The following
case will highlight the management of DFS with particular attention
to diabetic foot infection.
C ASE
Mr. D is a 41-year old resident of Southwestern Ontario who
presented to a rural emergency department (ER) following a
penetrating injury to the plantar surface of his left foot. The patient
reported that he inadvertently stepped on a nail several days prior but
failed to notice his foot had been injured. Mr. D denied any pain and
disclosed that he has been diagnosed with T2DM for many years. In
addition to the wound on the left foot, physical examination revealed
the patient to be obese (BMI 44) with retinopathy, neuropathy, and a
diabetic ulcer on the right foot. His current medications are:
Metformin 1000 mg bid; Atacand 4 mg od; Losec 20 mg od; Lasix
40 mg od; Gabapentin 300 mg tid; Ditropan 5 mg bid; Vitamin D
1000iu od; Lantus insulin 51u hs; and Humalog 30u tid (adjusted +/2u). The ER physician cleaned the wound, confirmed a recent
tetanus vaccination and prescribed Cirpofloxacin 500 mg bid with
the explicit instructions for the patient to rest his foot.
One week following discharge, Mr. D re-presented to the ER,
reporting that his left foot appeared worse. Physical examination
revealed a grossly swollen, erythematous foot that felt warm to
touch. The ER physician diagnosed Mr. D with an infected diabetic
foot and performed an incision and drainage. A tissue specimen
wound culture was obtained and grew mixed flora. The patient was
admitted to hospital for IV antibiotics (Cirpofloxacin 500 mg bid and

Foot infections are very common in patients with diabetes. Together
with foot ulceration, foot infections have been identified as a major
cause of morbidity and mortality in the diabetic patient as well as a
major expense to health care systems.6,7 The propensity for diabetic
patients to develop foot infections can be attributed to three
pathological processes: neuropathy, vascular insufficiency and
diminished neutrophil function.8 Patients displaying symptomatic
peripheral neuropathy lose ability to sense pain in their lower
extremities and thus fail to notice the presence of an abrasion, blister
or penetrating trauma.9 In addition, the vascular insufficiency and
diminished neutrophil function impairs the immune response. 10
Together, these factors promote colonization of the wound by
pathogenic organisms and the spread of infection from the surface to
deeper tissue.8
The diagnosis of diabetic foot infection is made clinically based on
the presence of pus or at least two cardinal manifestations of
inflammation (erythema, warmth, swelling or induration, and pain or
tenderness). It is important to note that the presentation will vary
from patient to patient. If peripheral neuropathy is present, the
patient may report diminished or absent pain at the site of infection.
Furthermore, 50% of diabetic patients with a significant foot
infection will not have systemic signs of fever or leukocytosis due to
a blunted cellular response to the infection.11
Aggressive management of diabetic foot infections is crucial. Left
untreated, these infections progress to gangrene and eventually
require amputation of the limb. The wound should be cleaned,
debrided and probed to identify sinus tracts, abscesses and the
presence of osteomyolitis.9 Tissue specimens for wound culture
should be obtained by scraping the base of the ulcer with a scalpel
blade and processed for a Gram stained smear and aerobic/anaerobic
cultures.12 Initial antibiotic therapy is empiric, broad spectrum and
based on the severity of the infection. Severe infections require
agents with coverage against Gram positive (including MRSA if
necessary), Gram negative and anaerobic organisms. The patient
should be evaluated for response to therapy in 1-3 days. If indicated
by early culture results a modification to their antibiotic regimen can
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occur at this time. Severe diabetic foot infections often require
surgical management including incision and drainage, surgical
debridement, revascularization and amputation.9 Following
treatment, appropriate wound care is essential. Removing pressure
from the wound, minimizing leg edema and maintaining a moist
wound environment are all important factors that promote wound
healing.13,14,15
Of all the diabetes related hospital admissions in North America,
DFS accounts for 20%.16,17 A focus on the prevention of DFS in
diabetic patients will not only improve the quality of life of those
patients but also help reduce the burden diabetic patients place on
health care systems. It is recommended that diabetic patients engage
in regular foot examinations.18 Higher risk individuals require foot
care education regarding the avoidance of foot trauma, properly
fitted footwear, smoking cessation strategies and optimization of
glycemic control.19 Those who develop foot ulcers require
management by multidisciplinary teams involving individuals
specialized in diabetic foot care.20
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A 19 year old with a bilateral posterior subcapsular cataract (PSCC) induced by
corticosteroid cream  
Abdul Naeem (Meds 2014)
Faculty Reviewer: Dr. Baseer Khan MD, FRCSC (Department of Opthalmology and Vision Services, University of
Toronto, Mount Sinai Hospital, Clarity Eye Institute)
C ASE
We present a case of a healthy 19 year old female on a three month
follow-up to our clinic with a bilateral posterior sub-capsular cataract
(PSCC) induced by a corticosteroid cream she used for one month
due to her atopic dermatitis. All remaining medical history and
systems review are normal. She is currently not on any medications.
In her right (OD) eye her uncorrected vision (sc) is CF @ 4 ft,
corrected vision (cc) is 20/40 and IOP is 12. In her left (OS) eye her
uncorrected vision is 20/400, corrected vision (cc) is 20/70-2 and
IOP is 13.

D ISC USSI O N
Cataract is the leading cause of blindness in the world.1 A cataract
(from the Latin cataracta meaning waterfall) is defined as the
clouding of the crystalline lens of the eyes. In normal healthy
humans, the lens of the eye is usually clear whereas a person with
cataracts may have a lens varying from slight to complete opacity.
Until the fourth decade of life, the lens is able to change its shape.
This allows the lens to focus on near and far away objects. The lens
focuses the light rays on the back of the eye and the light signal is
transmitted to the brain via the optic nerve.
In normal humans since embryonic development and onwards the
lens of the eyes produce specialized cells that are arranged in a
specific and complex orientation.2 These cells in the lens of the eye
are stratified epithelia and contain large amounts of cytoplasmic
proteins. These proteins are called crystallins and are transparent.2
However, the lens are unique in the sense that they "do not shed
nonviable cells"3 and so the "lens is susceptible to degenerative
effects of aging on cell structure"3. And so subsequently with
advanced aging of the lens, the lens becomes cloudy. This
cloudiness or cataract can then obstruct the passage of light and in
effect cause deviation from normal vision.
Factors that may lead to cataract formation are: advanced age,
smoking, alcohol consumption, poor lifestyle habits (including
malnutrition and physical inactivity), long-term exposure to
ultraviolet light or radiation, congenital factors, surgical
complications, corticosteroid drugs, and secondary effects of diseases
such as diabetes, hypertension and trauma.4,5
In the case presented, the cause of cataracts was eye exposure to a
corticosteroid cream used for atopic dermatitis. Corticosteroids are
heavily used for treating localized and systemic inflammatory
conditions in dermatology. The administration methods are usually
topical, oral or inhaled. Corticosteroids affect a large spectrum of
bodily systems and specifically may result in an early forming

  

cataract and an increase in intra-ocular pressure (IOP), which is a
risk factor for Glaucoma. With this in mind, corticosteroids should
be prescribed with time spent on patient education and possible
treatment complications.
The patient presented in this case was monitored for IOP, which was
noted as stable and normal. However, she did develop a sub-capsular
cataract, which is formed in the posterior portion of the lens. This
type of cataract is "particularly visually disabling"6 as it is formed
"nearest to the eye's focusing or nodal point". 6 In terms of
corticosteroid administration, "topical steroids have the most effect
followed by oral/parenterally administered formulations".6 There is
some research also suggesting that inhaled corticosteroids may lead
to cataract formation as well.
In conclusion, though cataracts can be quite disabling and can
significantly affect the quality of life of a patient, they do not damage
the eye. With the technological advances in cataract surgery,
cataract extraction can be successfully managed with an outpatient
procedure.7,8 Patients are usually seeing a lot better within 24 hours.
Considerations for surgery, risk factors, and options for intra-ocular
lens, were discussed with our patient. In this case, the patient still
had quite a bit of manageable vision and decided to watch and wait
for now. A follow-up of 6 months was scheduled when her eyes will
be reassessed and operated on if she agrees and meets the surgical
indications. Indications for surgery would include difficulty with
routine daily activities of living, school or driving.
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